[18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour Abstract #1381

Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Aim(s): To evaluate the correlation between FP and response to chemotherapy (CHT) and everolimus (E) for pancreatic NETs (PanNETs).
Materials and methods: Baseline and post-treatment imaging studies (contrast enhanced CT/MRI and FP) of 31 patients (P) treated for advanced, G1-2 PanNETs were retrospectively reviewed. A per lesion analysis was conducted, separately for each treatment arm (CHT and E), selecting up to 6 lesions (L) for each P. Baseline FP results (positive if SUV max > 3.5) and RECIST1.1 disease control rate (DCR) and objective response rate (ORR) were analyzed for possible correlations.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani

To read results and conclusion, please login ...

Further abstracts you may be interested in

#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#465 Management of an Advanced Pancreatic Neuroendocrine Tumor
Introduction: Whereas an array of treatment modalities have evolved for management of pancreatic NETs, there has been a lack of information regarding a clear algorithm of optimal treatment or an appropriate sequence in which different treatment modalities can be applied to a given patient for optimal results.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, Al-Hindi H, ...
#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
Keywords: everolimus
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.